Enliven Therapeutics (NASDAQ:ELVN) Given New $59.00 Price Target at The Goldman Sachs Group

Enliven Therapeutics (NASDAQ:ELVN) had its target price lifted by The Goldman Sachs Group from $41.00 to $59.00 in a research report sent to investors on Friday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

ELVN has been the topic of a number of other research reports. Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 3rd. Mizuho increased their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 25th. HC Wainwright increased their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.80.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $40.75 on Friday. Enliven Therapeutics has a 1 year low of $14.78 and a 1 year high of $48.53. The firm’s 50 day moving average price is $37.05 and its 200 day moving average price is $27.33. The firm has a market cap of $2.48 billion, a P/E ratio of -24.40 and a beta of 0.32.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. As a group, equities analysts predict that Enliven Therapeutics will post -1.7 EPS for the current year.

Insider Buying and Selling

In other Enliven Therapeutics news, Director Richard A. Heyman sold 1,230 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the transaction, the director owned 22,647 shares of the company’s stock, valued at $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 10,000 shares of the stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 25.90% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently made changes to their positions in the business. KBC Group NV purchased a new position in shares of Enliven Therapeutics in the 1st quarter valued at $38,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after acquiring an additional 594 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Enliven Therapeutics in the 4th quarter valued at $83,000. Finally, Quantbot Technologies LP raised its stake in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.